Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average of $1.46

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.46 and traded as low as $1.30. Spero Therapeutics shares last traded at $1.30, with a volume of 80,228 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Spero Therapeutics in a research note on Tuesday, August 6th. TD Cowen upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday, August 6th.

Spero Therapeutics Price Performance

The firm has a market cap of $70.18 million, a price-to-earnings ratio of 3.02 and a beta of 0.62. The firm has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $1.46.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Monday, August 5th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. The firm had revenue of $10.20 million during the quarter, compared to the consensus estimate of $9.80 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. Equities analysts anticipate that Spero Therapeutics, Inc. will post -1.59 earnings per share for the current fiscal year.

Institutional Trading of Spero Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after buying an additional 9,675 shares during the last quarter. Murchinson Ltd. boosted its stake in Spero Therapeutics by 1.3% during the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after buying an additional 11,210 shares during the last quarter. Virtu Financial LLC acquired a new position in Spero Therapeutics during the first quarter worth $31,000. Renaissance Technologies LLC boosted its stake in Spero Therapeutics by 14.2% during the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after buying an additional 121,492 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Spero Therapeutics by 40.6% during the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after buying an additional 309,262 shares during the last quarter. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.